
Sign up to save your podcasts
Or


In our latest update, We discuss the results of a one year Phase I trial exploring the use of a tyrosinase inhibitor in an hydrogel implant for the treatment of neovascular AMD with Dr. Andrew Moshfeghi, Associate Professor of Ophthalmology, USC Roski Eye Institute.
By Retina Synthesis4.5
88 ratings
In our latest update, We discuss the results of a one year Phase I trial exploring the use of a tyrosinase inhibitor in an hydrogel implant for the treatment of neovascular AMD with Dr. Andrew Moshfeghi, Associate Professor of Ophthalmology, USC Roski Eye Institute.

18 Listeners

2,445 Listeners

112,802 Listeners

674 Listeners

56,532 Listeners

596 Listeners

4 Listeners

11 Listeners

51 Listeners

10 Listeners

18 Listeners

2 Listeners

0 Listeners

840 Listeners